SEC Form SC 13G/A filed by Invivyd Inc. (Amendment)
$IVVD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/5/2024 | $9.00 | Neutral → Buy | Guggenheim |
| 3/26/2024 | $4.00 → $10.00 | Equal-Weight → Overweight | Morgan Stanley |
| 12/19/2023 | $1.00 → $4.00 | Underweight → Equal-Weight | Morgan Stanley |
| 5/1/2023 | $5.00 | Buy | H.C. Wainwright |
Guggenheim upgraded Invivyd from Neutral to Buy and set a new price target of $9.00
Morgan Stanley upgraded Invivyd from Equal-Weight to Overweight and set a new price target of $10.00 from $4.00 previously
Morgan Stanley upgraded Invivyd from Underweight to Equal-Weight and set a new price target of $4.00 from $1.00 previously
S-3 - Invivyd, Inc. (0001832038) (Filer)
8-K - Invivyd, Inc. (0001832038) (Filer)
SCHEDULE 13G - Invivyd, Inc. (0001832038) (Subject)
NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr. Bolno is the President and CEO of Wave Life Sciences, a clinical-stage biotechnology company, and has served in those roles since 2013. "We are happy to have Dr. Bolno join our Board at this critical moment while we transition toward a future focused on helping large populations avoid becoming ill from major viral infectious diseases," said Marc Elia, Chairman of the Board of Invivyd. "Dr. Bolno's extensive experience in leading Wave Life Sciences through rapid pipeline developm
NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced the appointment of Kristie Kuhl as Chief Communications Officer. Ms. Kuhl will lead the Company's communications and patient advocacy efforts as Invivyd advances its mission of providing monoclonal antibodies for the prevention and treatment of viral disease. Ms. Kuhl brings deep expertise in healthcare and pharmaceutical communications, and she has been recognized by industry media for her influence in health communications, including PRWeek's 2024 Health Influencer 30. She most recently served as Global Managing Director, Health & Wellness at Zeno Group, where she led the firm's healthcare p
SPEAR proposal reflects current evidence on monoclonal antibodies in treatment for Long COVID and identifies VYD2311 as a promising next-generation candidate for the clinical study Recommendation is for a robust, comprehensive, translational study to evaluate the ability of VYD2311 to decrease circulating spike protein in eligible patients and to explore potential associated clinical benefits Study design contemplates maintaining high antiviral antibody titers over an extended period to maximally suppress underlying chronic infection that may drive Long COVID pathologyDrs. Amy Proal and David Putrino to present on behalf of SPEAR Study Group WALTHAM, Mass., Sept. 04, 2025 (GLOBE NEWSWIR
4 - Invivyd, Inc. (0001832038) (Issuer)
3 - Invivyd, Inc. (0001832038) (Issuer)
4 - Invivyd, Inc. (0001832038) (Issuer)
NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr. Bolno is the President and CEO of Wave Life Sciences, a clinical-stage biotechnology company, and has served in those roles since 2013. "We are happy to have Dr. Bolno join our Board at this critical moment while we transition toward a future focused on helping large populations avoid becoming ill from major viral infectious diseases," said Marc Elia, Chairman of the Board of Invivyd. "Dr. Bolno's extensive experience in leading Wave Life Sciences through rapid pipeline developm
NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced the appointment of Kristie Kuhl as Chief Communications Officer. Ms. Kuhl will lead the Company's communications and patient advocacy efforts as Invivyd advances its mission of providing monoclonal antibodies for the prevention and treatment of viral disease. Ms. Kuhl brings deep expertise in healthcare and pharmaceutical communications, and she has been recognized by industry media for her influence in health communications, including PRWeek's 2024 Health Influencer 30. She most recently served as Global Managing Director, Health & Wellness at Zeno Group, where she led the firm's healthcare p
WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist focused on transformational companies that have solved critical problems in healthcare, technology, and energy. Mr. Royan's investment firm, Mithril, is a significant long-term holder of Invivyd stock, and Mr. Royan led the 2022 shareholder action that focused Invivyd on its mission to deliver protection from serious viral infectious diseases, starting with COVID-19. "We are delighted by Ajay's return to the Board of Invivyd as the company prepares to take the next step forward in scaling the medica
SC 13D/A - Invivyd, Inc. (0001832038) (Subject)
SC 13G/A - Invivyd, Inc. (0001832038) (Subject)
SC 13G/A - Invivyd, Inc. (0001832038) (Subject)
PEMGARDA™ (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales forcePEMGARDA revenue re-acceleration observed in Q2 2025 to dateInvivyd continues to target near-term profitability (1H 2025) with existing cash and cash equivalents, anticipated growth of net product revenue, and continued reduction of operating expensesSince Emergency Use Authorization (EUA) of PEMGARDA in March 2024, no documented cases of anaphylaxis reported, across thousands of post-authorization dosesVYD2311 Phase 1 clinical trial data read-out anticipated later in Q2 2025 WALTHAM, Mass., May 15, 2025 (GLOBE NEWSWIR
WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 15, 2025, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2025, and provide recent business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this link and are advised to join 15 minutes prior to the start time. A replay of the webcast will be available via the company's investor relations website approximately two
Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with $106.9 million in cash and cash equivalentsTargets near-term (1H 2025) profitability with existing cash and cash equivalents, anticipated growth of net product revenue, and various operational efficiency improvementsPEMGARDA Fact Sheet updated to properly reflect neutralization activity of PEMGARDA against current circulating variants tested; on track for continued growth now reflective of ongoing commercial optimizationNext generation molecule VYD2311 first-in-human clinical trial dosing began in August 2024 with anticipated preliminary data readout late Q4 2024Management to host conference call t